{
    "2019-12-09": [
        [
            {
                "time": "2018-03-15",
                "original_text": "J&J CEO Gorsky spurns U.S. congressional hearing on carcinogens in talc products",
                "features": {
                    "keywords": [
                        "J&J",
                        "CEO",
                        "Gorsky",
                        "spurns",
                        "congressional",
                        "hearing",
                        "carcinogens",
                        "talc"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "Johnson & Johnson Emerging Out Of A Dark Place",
                "features": {
                    "keywords": [
                        "Johnson",
                        "&",
                        "Johnson",
                        "Emerging",
                        "Dark",
                        "Place"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-20",
                "original_text": "Amgen Gets FDA Approval for J&J/Merck's Remicade Biosimilar",
                "features": {
                    "keywords": [
                        "Amgen",
                        "FDA",
                        "Approval",
                        "J&J",
                        "Merck",
                        "Remicade",
                        "Biosimilar"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-12-09",
                "original_text": "J&J Presents Data on CAR-T Therapy Drug and Imbruvica at ASH",
                "features": {
                    "keywords": [
                        "J&J",
                        "Presents",
                        "Data",
                        "CAR-T",
                        "Therapy",
                        "Drug",
                        "Imbruvica",
                        "ASH"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-11-25",
                "original_text": "Bluebird Bio Stock Is Rising on Promising Cancer-Drug Data",
                "features": {
                    "keywords": [
                        "Bluebird",
                        "Bio",
                        "Stock",
                        "Rising",
                        "Promising",
                        "Cancer-Drug",
                        "Data"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}